Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Haijing Wei"'
Autor:
Jingrui Liu, Xiaoxue Zhu, Hong Zhang, Haijing Wei, Deming Yang, Zhongnan Xu, Dandan Huo, Xiaojiao Li, Yanhua Ding
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: As a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, TQ-F3083 represents a promising new drug for type 2 diabetes mellitus (T2DM). This phase I, first-in-human study evaluated the tolerability, pharmacokinetics, and pharmacodynamics of TQ
Externí odkaz:
https://doaj.org/article/88320d38bf4a4660b4ac8c59888c2af2
Autor:
Hong Zhang, Hong Chen, Xiaojiao Li, Min Wu, Xiaoxue Zhu, Cuiyun Li, Jingrui Liu, Haijing Wei, Yue Hu, Jingjing Wang, Yongmin Yang, Xiangyang Zhu, Yanhua Ding
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Objective: This study explored the bioequivalence of a proposed biosimilar HOT-3010 vs. its reference product (adalimumab) among healthy Chinese male subjects. The study also investigated the tolerance, immunogenicity, and pharmacokinetics (PK).Metho
Externí odkaz:
https://doaj.org/article/6f224c8951024eb7a1b718617f5ddf51
Autor:
Hong Zhang, Hong Wang, Haijing Wei, Hong Chen, Jingrui Liu, Cuiyun Li, Xiaoxue Zhu, Xiaojiao Li, Jinchen Yu, Yinbo Zhou, Xiaolei Yang, Zhaohe Wang, Min Wu, Yanhua Ding
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2021)
Objective: The study aimed to explore the bioequivalence of a proposed biosimilar BAT1806 to its reference products marketed in the EU and US (RoActemra-EU and Actemra-US) among healthy Chinese men. The tolerance, immunogenicity, and pharmacokinetics
Externí odkaz:
https://doaj.org/article/2e161d9d824347e1a430fbf30cff2f95
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Background: Jaktinib is a novel selective janus kinase 1/2 inhibitor. The phase I first-in-human study evaluated the tolerance and pharmacokinetics of jaktinib in healthy Chinese subjects.Methods: A randomized, double-blind, placebo-controlled study
Externí odkaz:
https://doaj.org/article/b83546d016254240adece2e3186e58c6
Autor:
Xiaojiao Li, Cai Liu, Xiaoxue Zhu, Haijing Wei, Hong Zhang, Hong Chen, Guiling Chen, Deming Yang, Hongbin Sun, Zhenwei Shen, Yifan Zhang, Wei Li, Jin Yang, Yongqiang Liu, Xiaojuan Lai, Yanchun Gong, Xuefang Liu, Yongguo Li, Dafang Zhong, Junqi Niu, Bin Liu, Yanhua Ding
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Background: Vicagrel is a novel anti-platelet drug and hydrolyzed to the same intermediate as clopidogrel via esterase, instead of CYP2C19. Here we report the first clinical trial on the tolerability, pharmacokinetics and pharmacodynamics of differen
Externí odkaz:
https://doaj.org/article/e681599f5b63406da86ab78346c394a6
Autor:
Yanhua Ding, Deming Yang, Zhongnan Xu, Haijing Wei, Xiaoxue Zhu, Hong Zhang, Dandan Huo, Jingrui Liu, Xiaojiao Li
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Background: As a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, TQ-F3083 represents a promising new drug for type 2 diabetes mellitus (T2DM). This phase I, first-in-human study evaluated the tolerability, pharmacokinetics, and pharmacodynamics of TQ
Autor:
Min Wu, Cuiyun Li, Shirui Zheng, Hong Zhang, Hong Chen, Jingrui Liu, Hui Zhou, Haijing Wei, Yanhua Ding, Guiling Chen, Xiaoxue Zhu, Xiaojiao Li
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 57:167-174
Objective To compare the pharmacokinetic (PK) profiles, immunogenicity, and safety of the proposed biosimilar IBI305 with those of bevacizumab in healthy male subjects. Design A phase I, randomized, double-blinded, two-arm, parallel-group study. Sett
Autor:
Yanhua Ding, Min Wu, Jingrui Liu, Cuiyun Li, Xiangyang Zhu, Yongmin Yang, Hong Zhang, Hong Chen, Xiaoxue Zhu, Yue Hu, Haijing Wei, Xiaojiao Li, Jingjing Wang
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
Objective: This study explored the bioequivalence of a proposed biosimilar HOT-3010 vs. its reference product (adalimumab) among healthy Chinese male subjects. The study also investigated the tolerance, immunogenicity, and pharmacokinetics (PK).Metho
Autor:
Jingrui Liu, Cuiyun Li, Li Liu, Hong Chen, Min Wu, Ting Liu, Haijing Wei, Xiaojiao Li, Hong Zhang, Yanhua Ding
The study aimed to explore the bioequivalence of a proposed biosimilar HL02 vs. its reference products (US-trastuzumab) among healthy Chinese men. In this study, nine healthy male subjects received single ascending doses of trastuzumab biosimilar (HL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ed9fd40f533762d2a695672a32fa475
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Frontiers in Pharmacology
Frontiers in Pharmacology
Background: Jaktinib is a novel selective janus kinase 1/2 inhibitor. The phase I first-in-human study evaluated the tolerance and pharmacokinetics of jaktinib in healthy Chinese subjects.Methods: A randomized, double-blind, placebo-controlled study